



I'm not robot



Continue

## Video game live wallpaper android

Customizing your smartphone's wallpaper is an effective way to cement your smartphone's home screen as an integral part of your life. An attractive static home screen wallpaper background can make your device's experience more positive, optimistic and exciting to use. Live wallpaper —which moves like a GIF as you play and secure—makes your Android or iPhone user experience even more interesting. Some smartphones come with built-in live wallpapers, but it only takes a few minutes to make your own custom live wallpaper from any video you have. Think about how inspiring it would be to see that hummingbird you filmed flying your wings whenever you launch your phone. Does that sound tempting? We explain how to make live wallpaper for iPhone and Android. We show you how to do this natively on iPhone, without having to download live wallpaper apps. We also cover how to do this with third party apps on Android — the only way to achieve this on Android.How to create live wallpaper on iPhone iPhone Wallpaper SettingsChoosing Live Photos for wallpaperSing live wallpaper iPhoneSetting live wallpaper iPhoneIf you have an iPhone 6S or later, you can make a live wallpaper on iPhone natively without having to download an app. That's because the iPhone 6S and later models (not including the first generation of iPhone SE) allow you to take live photos and also activate 3D or Haptic Touch. Live Photos are very short snippets of video that allow you to edit and choose the perfect frame for your photo. However, they can also be used as live wallpaper. Here's how to do it in iOS 13 and iOS 14.**Step 1:** Go to Settings &gt; Wallpaper.**Step 2:** Tap Choose a new wallpaper. Scroll down and tap Live Photos. **Step 3:** Select a photo. Make sure you have Live Photo: On enabled. **Step 4:** Tap Set. Choose set lock screen or set both. Set Home Screen is not critical, since the wallpaper will not actually move on the home screen. Once done, you will have a live wallpaper that animates on the lock screen when you tap and hold the image. You can also use a number of iOS apps to save a GIF or video as a Live Photo, which you can set as a live wallpaper. For example, InoLive is a popular app for iOS that can convert your videos into Live Photos as well as Giphy.How to create live wallpaper on AndroidVideo Live Wallpaper AndroidWallpaper AndroidWallpaper live wallpaper settingsTo create a live wallpaper on Android, you must download a third-party live wallpaper application. There are several of them currently available, with some of the most popular including IdoItSolutions Live Wallpaper, KLWP Live Wallpaper Maker, GIF Live and Wallopo's Live Wallpaper Maker, GIF Live and Wallopo's Live Wallpapers HD &amp; Backgrounds 4K/3D. There is also a wide range of automated live wallpaper apps that make and define different live wallpapers for you. For example, muzel live wallpaper updates your Android smartphone every day with a new live wallpaper based on a famous work of art. Meanwhile, Forest Live Wallpaper provides you with forest themed live wallpapers. However, if you want to make your own live wallpapers on Android, here's how to use Video Live Wallpaper to do so.**Step 1:** Open the app and tap Gallery. Select the video you'd like to set as a live wallpaper. **Step 2:** Choose the settings you like for the live wallpaper. There is an option to Play Audio, which is probably not the best idea if you want to save battery or be discreet. You can also choose to loop the video so that it plays repeatedly. You can even choose to play the video screen, which keeps the live wallpaper running even when you're in an app. **Step 3:** After choosing the settings you want, tap Set live wallpaper. That's it. While there are many similar live wallpaper apps out there — Video Live Wallpaper is well checking out — they all work more or less the same way. Try it and, above all, have fun. One of America's largest mortgage providers has lowered the bar again. This article will explain what cents are and discuss four cents below \$1 to watch as small cap stocks continue a hot wave this winter. The first thing is, what are cents? In short, these are shares of companies that trade for less than \$5. Penny's shares are well known for their volatility, as well as just their cheap price. But if you're looking at stocks below \$1 or a closer to \$5, it's important to keep a few things in mind. First, understand what you're buying and why you're buying. Just saying that trading stocks isn't the goal. You're in the market to make money. So identifying inbound and outbound targets are obviously important. Also, it's that you should have a basic strategy in mind. Are you looking at the day trading pennies or do you have a long-term idea in mind? In addition, it is important to explain the fluctuations in price and how quickly they are happening. Small-Cap shares continue their hot streak Why would anyone want to buy pennies now? Be sure in point, small cap stocks are very hot right now. Check out the reference ETF, the Russell 2000 (IWM). As the \$&skamp;P, Dow and even nasdaq struggle to maintain an uptrend, the IWM made new all-time highs on Wednesday. Considering the strength in small cap stocks - especially stocks below \$1 - it's prudent to at least have some trend names on your watch list. When finding pennies to buy, be sure to evaluate each trade independently and plan accordingly. Most did not plan to invest in cent stocks that are rising and falling 50% in seconds. Also, day traders wouldn't trade in cent stocks that are rising and falling 50% in seconds. This is simply because a small movement in price equates to a larger percentage change. With that in mind, are any of these stocks below \$1 on your watch list right now? Tonix Pharmaceuticals Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNPX) is another stock of cents below \$1 gaining steam before the of the year. This week, the company came out with the news that it has finished buying about 44 acres in Montana. This will be the place for the development and manufacture of vaccines. This also increases the company's growing footprint. A few months ago, Tonix also purchased a 40,000-square-foot facility in Massachusetts. These two facilities will support the development and production of the company's vaccine candidate. If you are new to the history of TNPX's actions, the company is currently developing the TNX-1800 as a potential COVID-19 vaccine as well as TNX-801 for a smallpox/malpix vaccine. Specifically, the TNX-1800 has been a center of attention as you can imagine. Many stocks of coronavirus vaccines have aroused interest in recent months. In this case, Tonix intends to report efficacy data from animal challenge studies of the vaccine candidate in the next quarter. Biolase Biolase Inc (NASDAQ: BIOL) is another of the lower-priced cent stocks that make moves at the end of the year. Just this week, the currency's shares rose from about \$0.27 to more than \$0.31. Although this is only a move of \$0.04, it equates to a nearly 15% jump in price since Monday. Unlike other biotechnologies, Biolase is mainly focused on products used in oral health. The company's main products are dental laser systems that perform a wide range of procedures, including aesthetic and complex surgical applications. Last month, the company launched The Waterlase Endo Academy to promote education and best practices for integrating Waterlase technology into clinical environments. As endodontists continue to seek more advanced solutions to challenging cases, the academy will serve as a resource for some of the greatest minds in the field to elevate the spread of best practices for integrating advanced technologies like Waterlase, said Todd Norbe, president and CEO of Biolase.Jaguar Health Inc. (NASDAQ: JAGX) continued to rise this week. Wednesday saw the cent shares further extend their December earnings and reach highs of more than \$0.90. Although we've reported on the company for weeks, this week's biggest move comes after Jaguar's latest update. The company signed an agreement for an unutilized royalty financing transaction. Jaguar will sell a stake in future royalties from its Mytes® (crofelerem) and leclhemer for an aggregate purchase price of \$6 million. Lisa Conte, President and CEO of Jaguar, explained that: The timing of this transaction is aligned with the progress of the recently initiated phase 3 cid test, for which patient enrollment is progressing. Also remember that the company held preliminary discussions with the Swiss Group Forum, sponsor of a European special purpose acquisition company, Post Pandemic Recovery Equity. There is a potential agreement with the and an operational subsidiary of Jaguar to be established in Europe with an exclusive license to crofelerem and Mytes for indications of inflammatory diarrhea and hiv-related hiv-related Holdings Inc. (NYSE: SENS) started shooting this week after a major U.S. patent victory. Senseonics has received a patent entitled Remotely powered sensing system with multiple sensing devices. Considering that the company is a medical device company, patent wins are very useful. Senseonics implantable glucose monitoring systems are used by patients with diabetes. The company's CGM systems, Eversense® and Eversense® XL, include a small sensor inserted under the skin. This communicates with an intelligent transmitter used on the sensor. The data is then sent every five minutes to a mobile app on the user's smartphone. Adding to the reasons for watching senseonics, earlier this year the company entered into a collaboration with Ascensia Diabetes Care, a global diabetes care company. Going into early 2021, there are a few things that traders are following. One of these things is the start of commercial activities outside the U.S. with the help of Ascensia. The company also expects a decision on approval of its Eversense product by the FDA in the first half of the year. Neither the author of this post nor Pennystocks.com have a position or financial relationship with any of the actions mentioned above. See more of Benzinga \* Click here for Benzinga's trading options \* 6 Alternative Energy Stocks To Watch for the First Quarter of 2021 As Renewables Heat Up(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved. The infiltrators are very interesting. From the investor's point of view, corporate directors have access to information – and information has always been the key to investment success. The company's CEOs, executive VPs, board members – are privileged positions, officers in a position to know what is happening, or probably happen, with a company and its actions. And yes, they trade the company's shares. They are aware of the inner workings of their companies, and this knowledge puts them in a much better position than the general public to make purchasing decisions about their corporate actions. To maintain the level of play in the market, federal regulators require corporate directors – insiders – to publicly disclose their negotiations to the companies they run. In a few years, following corporate insiders is a viable path to profitable stock movements. To facilitate this search, TipRanks Insiders' Hot Stocks tool begins to work based – identifying actions that have seen informative movements by insiders, highlighting various common strategies used by insiders, and collecting data in one place. Fresh from this database, here are the details about three Strong Buy stocks showing informative purchases in recent days. Vistra Energy (VST) The first internal choice here, Vistra is a public service company based in Texas. Vistra offers a full range of electricity services, including power generation, transmission and distribution. The company is of course an essential industry, giving it an edge during the ongoing corona crisis, and vistra vistra's revenues a quick recovery from a modest dip in the second quarter. This recovery was substantial. Third-quarter revenue sat at \$3.55 billion, up 40 percent from the second quarter and 11 percent from the previous quarter. The company's earnings were also solid, at 90 cents per share, and were the best in more than two years. Two of Vistra's directors have made recent purchases of prime shares – Chairman and CFO James Burke and Board Member Scott Helm. Burke bought 17,000 shares for which he paid more than \$310,000. Helm, in turn, paid more than \$356,000 for two blocks of 10,000 shares each. Supporters include BMO analyst James Thalacker, who classifies VST as Outperform (i.e. Buy) along with a price target of \$29. This figure suggests a 57% increase in one year. (To watch Thalacker's history, click here) Thalacker takes note of the company's solid performance in q3, and its potential for a strong end to the year, noting: We attributed strong performance in generation to a more favorable coverage environment last summer when the company entered its 2020 hedges. In addition, with a very light summer at ERCOT, we suspect that VST may have had the opportunity to optimize its generation portfolio by running less of its own higher heat rate energy units and buying energy in the spot market. The analyst added: We are keeping our estimate of \$3.59 billion (already in the upper half) as we wait to see how energy conditions develop in the coming weeks. Overall, Vistra Energy holds a strong buy rating from analysts' consensus, based on 6 recent ratings breaking 5 to 1 Buy vs. Hold. The share price of \$18.47 and the average price target of \$29 are the upside –57%, equating Thalacker's for next year. (See VST stock analysis in TipRanks) Grid Dynamics Holdings (GDYN)Next, Grid Dynamics is a high-tech company that offers digital transformation services. Grid's services include solving legacy replatform issues, technology engineering, and moving to the cloud. The company has a global customer base, and is headquartered in Silicon Valley.Grid became public on the NASDAQ in March this year through a merger with a special-purpose acquisition company, ChaSerg Technology Acquisition Corporation. When the transaction closed, Grid boosted a market capitalization of \$660 million. Stocks fell sharply in the early trading days, coinciding with COVID's impact on the economy and stock markets at the time. Since then, GDYN's shares have risen, and shares have risen more than 120% compared to its March trough. The impact of the crown can still be felt for Grid, however. While revenues in the third quarter increased 18% sequentially in the second quarter, the \$26.33 million reported was still lower in the first quarter. The company reported strong revenue growth in its non-retail and vertical technology industry. The remarkable internal move here comes from Victoria Livshitz, EVP of Customer Success, who bought 126,000 shares last week. She disbursed \$1.48 million for the stock block, and now has a stake in GDYN worth \$10.65 million. Joseph of Canaccord Canaccord is impressed by Grid's forward prospects. The 5-star analyst notes: We believe Grid's customer pool will be more robust and growing versus pre-pandemic, driven by strong spending on digital transformation by healthy and growing customers in TMT and CPG. Retail, desamirada, maintains an attractive option value, but will no longer be weighted by exposure to material revenue in a slightly impaired and defensive vertical. To do this, Vafi rates GDYN a Buy along with a price target of \$15. At current levels, your goal implies a potential 12-month lead of 21%. (To watch Vafi's history, click here) Research says... Wall Street agrees. A total of four of the ratings published in recent weeks say gdyn is a strong buy. However, the share's average price target of \$12.75 suggests a modest 3% advantage and a change from the current stock price. (See GDYN stock analysis in TipRanks) Arvinas Holding Company (ARVN)From high technology we switch to biotechnology, where Arvinas is an innovator in the biopharmaceutical field. The company is working on protein degradation therapy, a new class of drugs that targets disease-related proteins and uses the body's own natural protein elimination systems to break down and remove problematic proteins. As with most research-based biopharmaceutical companies, Arvinas is all about the pipeline. The pipeline here is early stage but robust, presenting no fewer than 13 programs in the areas of oncology, immuno-oncology and neuroscience. Candidates for developing drugs are in various stages of initial research, from exploratory clinical trials to Phase 1. In recent days, ARVN shares have risen, more than doubling the stock price. The jump came after the company released clinical data showing the potential efficacy of two pipe drugs; ARV-471 for the treatment of patients with locally advanced or metastatic breast cancer, and ARV-110 for the treatment of men with metastatic castrate-resistant prostate cancer. Also in recent days, Arvinas announced the pricing of a new issue of common shares. The company is putting 5.714 million shares on the market at \$70 each, a move to raise \$400 million in new capital. And that brings us to insider trading. Board member Liam Ratcliffe spent \$9.99 million on 142,857 shares during the new common share offering. His total stake in ARVN is now \$58.46 million. In a statement from Roth Capital, analyst Zeegeh Jahlah writes: We like the management's outline of important next steps, which we believe will highlight how Arvinas plans to develop [ARV-110 and ARV-471] to boost value, and build its pipeline at an early stage... The company's pre-clinical pipeline is a basis to its strong market position. Jahlah gives the stock a buy rating, and its price target of \$120 implies a strong 60% gain over the year lead of 50%. (To watch Jahlah's history, click here) It's not always that all analysts agree to a stock, so when they do, it's worth noting. Strong Purchase of ARVN ARVN rating is based on a 9 unanimous purchases. The average share price target of \$102.44 suggests it is 78% ahead next year. Currently, the shares are trading at \$79.74. (See analysis of ARVN's actions in TipRanks) To find good ideas for stocks traded at attractive valuations, visit TipRanks' Best Stocks to Buy, a newly launched tool that unites all of TipRanks' stock insights. Notice: The opinions expressed in this article are exclusively from the prominent analysts. The content is intended to be used for informational purposes only. It is very important to do your own analysis before making any investment. Technology stocks along with banks, aerospace, retail and many other industries have had their day in the sun and now is the time for investors to pay more attention to a dream market for alternative fuel companies, according to Jim Cramer.Hydrogen Power. At the top of the list are potential energy giants of the future like Plug Power Inc (NASDAQ: PLUG) , said Cramer Tuesday on Mad Money. The hydrogen fuel cell company saw its stock skyrocket more than 1,000% by 2020. Bloom Energy Corp. (NYSE: BE) rose 300 percent, while Ballard Power Systems Inc (NASDAQ: BLPD) rose 200 percent. EV Play: Autonomous electric vehicles will not be possible without companies that manufacture the technology that powers the cars. Lumina Technologies Inc (NASDAQ: LAZR) is a manufacturer of laser-based sensors and competes against Velodyne Lidar Inc (NASDAQ: VLDR). EV cars will need access to the charging stations. The president is demanding payments of \$2,000, not \$600. What can he do? Having a home may be the epitome of the American dream, but it's not engraved in stone! So if you have to play with the idea of giving up your own home, then by all means, go ahead. However, given that property is perceived as the hallmark of wealth, giving up on it is set to bring you a lot of controversy. Individuals in your circle may even criticize. But regardless of what the larger population thinks, here are good reasons to never buy a house. Property costs are lifelong advocates for house ownership often argue that paying rent is expensive, but the property is equally so expensive. House costs do not end with its initial payment. It comes with life-long costs, which, compared to rent, will create a dent in your finances and take away your peace of mind. For example, bills for utilities such as electricity and water are inevitable and must be paid every month. According to Zillow, these accounts alone cost homeowners between \$2,300 and \$4,600 a year. Add recurring costs like insulation, heating and cooling costs, homeowners insurance, property taxes, HOA fees, mortgage payments and yard maintenance, and chances are you end up spending more annually than a tenant residing in a house similar to yours. Besides, there's no way to opt out. Once you buy a house, you commit to these costs unless you sell it. On the other hand, when you rent or rent a house, you can always choose to leave. For example, when times become difficult, you can always switch to income-based apartments until you're back on your feet again. A house is not a real estate investment pro-people will try to try you that your house is an investment. Although there is some truth to this, buying a house as your main residence is not the same as buying one for rent or resale. Because? Well, when you buy a house for real estate, it brings a return on investment. For example, when you buy a condo and rent it, you're back on the investment at least every 6 months based on the terms of your contract with your tenant. But when you buy a house to live in, you will have invested, but you will have no return. If anything, you will be the one putting money into it through maintenance, mortgage payments, and all other costs mentioned earlier. Also, a house can never be an investment if you don't plan to sell it in any time. What makes an investment an investment is your control over your property. In other words, a real estate investment is referred to as such because you can buy it when its value is low and sell it when the value is high, making profits. But your main residence is different because you can't just wake up one morning and decide to sell it unless you're pressured for money, which in most cases means you'll accept any offer that leads to losses. Also, when you sign this house purchase agreement, your money is automatically blocked, and the only way to recover it is by selling it or taking a home equity loan. When you rent or rent, you can use your money, and you can use it to invest in opportunities that grow your wealth. Of course, you could argue that rent is expensive, but this is not a good reason to buy a house, since there are many modern, well-equipped and low-income apartments that will help you keep costs down. Housing values are not always high it is true that a house increases in value over time. Due to inflation, a house bought for \$100,000 is now worth more than \$600,000. That means selling it will bring good profits. However, keep in mind that the housing market is incredibly volatile. The value of your home may be high now, so it can drop precipitously due to a drop in the housing market and/or other external factors. For example, during the great financial recession of 2007-2009, real estate market values suffered a sharp decline, which saw sellers suffer huge losses. Existing listing values fell from \$7.1 million to \$4.1 million, marking a 25% drop in the value of homes sold during this period. What does that have to do with buying a house? Well, you can buy a house waiting for it to increase in value, but instead, find out that its value is incredibly low when you need to sell it. You end up selling at a loss. Keep in mind that there are factors are out of your control. For example, the Real estate may not fall, but due to other components like increased crime, the value of homes in the neighborhood in which you bought your house decreases. Such an occurrence will make it almost, if not, impossible to find a buyer who is willing to out of their hands, even at a purchase price. In other words, unless you have a magic crystal ball, there is no telling what will happen next with the general, or your local real estate market. So if you are buying a house now with hopes that its value will increase in the future, then you'd better not buy one because you could potentially be massively disappointed. Owning a Home Ties You Down Unless you are rich and can buy a house in different parts of the country, the property connects you to a location. If you have a fantastic job or entrepreneurship opportunity, you may not just pack up and walk away. First, you have to put your house on the market and find a realtor to help you sell it. You also have to worry about market values, and since you are in a hurry to move to your next location, chances are that you will sell it to the first buyer because you don't have time to wait for better deals. But when you're renting, all you have to do is to pack up and leave. Even if you're not moving, buying a house automatically means you'll have to deal with the community around you for the rest of your life, especially if you don't plan to sell it. For example, even if you don't like your neighbors, you'll have no choice but to learn how to put up with them. When you rent and don't like your neighbors, the option to leave is always feasible. The property is not for everyone Not everyone is cut for home ownership. It comes with responsibilities that some people just don't have the skin to deal with. For example, when you buy a house, especially in a HOA community, you need to ensure that the yard is well maintained, clean gutters, repaint your exterior regularly, and other similar tasks. Not everyone is cut to that level of responsibility, and if that describes you, then never buy a house. The property doesn't set youOwning that the modern cond is great, but you can still enjoy living in it without having to deal with the stress of simply renting property. Home ownership does not define its success in any way. So if you never wanted a house, don't buy it because your peers own multiple houses. After all, home ownership leaves little to be desired. See more of Benzinga \* Click here for Trading Options from Benzinga \* Amazon Opening Three San Antonio Facilities \* The Psychology behind the M1 Finance platform and its focus on financial well-being (C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved. The executive chairman of Los Angeles-based startup Canoo said news of Apple's electric cars had a ripple effect through the EV space. Cloudera said it bought back all the stake Intel received in the software company for \$314 probably recording a substantial loss of paper for the chip giant in its investment. Can you feel the ground moving under your feet? Ocugen (OCGN) shares have risen more than 800% in the last three trading sessions after the biopharmaceutical company announced that it had signed a binding letter of (LOI) with India-based Bharat Biotech to co-develop a COVID-19 vaccine for the American market. The offer of COVAXIN, an inactivated COVID-19 vaccine candidate, has already shown promise in phase 1 and 2 clinical trials in India and the registration of 26,000 subjects for the Phase 3 study is underway. The agreement stipulates that Ocugen will hold the vaccine rights in the U.S., and the remaining details are expected to be finalized in the coming weeks. Considering Bharat's reputation for world-class R&amp;D resources and vaccine and bio-therapeutic manufacturing, H.C. Wainwright Swayampakula Ramakanth analyst thinks the company is an appropriate partner. Ramakanth believes that broad immunity targeting different components of the virus could potentially provide better protection against emerging mutant viruses, such as the one currently circulating in the UK. With this in mind, in phase 1 study, COVAXIN showed robust antibody responses against the spike protein (S), the receptor binding domain (RBD) and the nucleocapsid protein (N) of SARS-CoV-2. More importantly, the 5-star analyst added, COVAXIN also induces comparable levels of neutralizing antibodies to those of human convalescent serum, which, according to the analyst, is very important for the success of the ongoing Phase 3 test in India. In the coming weeks, Ocugen is expected to meet with the FDA to discuss how to advance the development of COVAXIN. However, due to the fact that the details of the definitive agreement have not yet been finalized, in addition to the current lack of discernment on the U.S. regulatory path or trade strategy, Ramakanth remains on the sidelines for now. Thus, the analyst evaluates the OCGN as Neutral (i.e. Hold) without suggesting a price target. (To watch Ramakanth's history, click here) In contrast, all 3 other analysts who recently posted an Ocugen review rate to buy action. However, the Strong Buy consensus rating is backed with a price target of \$0.9, which implies a 68% downside over current levels. This is probably the result of the meteoric rise in stocks and the inability of analysts to reverse new price targets so quickly. (See OCGN stock analysis in TipRanks) To find good ideas for coronavirus stocks trading with compelling reviews, visit TipRanks' Best Stocks to Buy, a newly launched tool that unites all of TipRanks' wealth insights. Notice: The opinions expressed in this article are exclusively from the prominent analysts. The content is intended to be used for informational purposes only. It's very important to do your own analysis before making any investment.2020 has been a year of monstrous gains for individual stocks, with companies like Tesla seeing a triple-digit increase. The turnaround of Business DailyGE Investor is winning over more believers on Wall Street, and the Boeing 737 Max returning to service soon. Ge's stock is a buyout now?2020 was a flag year for U.S. IPOs, even amid a global pandemic and financial crisis. The time will be for 2021, with the early debuts of Roblox and Affirm. Nikola's destruction continues. Today, the company announced the termination of its contract with Republic Services for 2,500 garbage trucks. Announced in August, the deal caused Nikola to build garbage trucks in 2023 with on-road testing scheduled for 2024. Na last week, modern-day Covid-19 vaccine candidate (MRNA) mRNA-1273 became the second vaccine approved in the U.S. after receiving emergency use authorization from the FDA. And on Tuesday, the director of the National Institute of Allergy and Infectious Diseases (Niaid), Anthony Fauci, received the first dose of the vaccine live on TV. However, contrary to the good news, coronavirus stocks were pressured this week by concerns that the current batch of vaccines will not be effective against a new Covid-19 strain that recently emerged in the UK. Modern is currently testing its vaccine against the new rapid-spread variant, but Wall Street's most prominent modern bear remains skeptical of the stock's prospects. Whether the vaccine proves effective against the new strain or not makes little difference to Leerink analyst Mani Foroohar. The analyst reiterated an Underperform rating (i.e. Sell) on MRNA shares, along with a price target of \$69. This figure implies a sharp drop of 47% compared to current levels. (To watch Foroohar's history, click here) Simply put, Foroohar believes that Modern's current estimates of evaluation and consensus have all the goodness already baked, which therefore distorts risk/reward sharply to the downside. The analyst expects stocks to remain volatile as investor debates about commercial and execution risk come to the fore. Modern's problem is further compounded by several other factors, says the analyst. The MRNA-1273 represents the majority of the company's revenue opportunity, and is the key driver of stock performance. In addition, the effort to fight the virus is a global concern that is likely to result in additional pressure from multiple sources. As we are in the midst of a global capacity building analogous to a Manhattan vaccine project, we summarized Foroohar: We see overcapacity, high competitive intensity, and limited-price power as likely long-term structural characteristics of the final vaccine markets, presenting secular challenges to a scale dwell player such as MRNA. What does the rest of the street think? Looking at the consensus break, the opinions of other analysts are more widespread. 7 Purchases, 7 Holds and 2 Sales add up to a Moderate Purchase consensus. In addition, the average price target of \$148.31 indicates ~14% upside potential. (See MRNA stock analysis in TipRanks) To find good ideas for health stocks trading with attractive valuations, visit TipRanks' Best Stocks to Buy, a tool that unites all tipranks stock insights. Notice: The opinions expressed in this article are exclusively from the prominent analyst. The content is intended to be used for information Just. It is very important to do your own analysis before making any investment. These are the main dividend stocks in the Russell 1000 with the highest future dividend yield for January. Ethereum (ETH) is the second largest cryptocurrency after Bitcoin (BTC) in terms of market capitalization. The cryptocurrency was launched on July 30, 2015, with Vitalik Buterin and Gavin Wood as its original authors. So how did this altcoin fare in the last half decade? Etherhall High: Assuming an investor bought \$1,000 in ETH on December 23, 2015, they would have picked up 1,162.79 units with an approximate price of \$0.86. Advancing only three years prior to January 13, 2018, when ETH reached its all-time high of 1,432.88 and this \$1,000 investment would have turned into \$1.67 million. Five years later, press time and \$1,000 would be worth \$709,740.70. The returns may not be as impressive as those of 2018, but it's still a gain of 70.974%. Even for ETH's early investors, the cryptocurrency triggered a return bonanza of 19,179.12%. The oldest known price for eth is \$2.77, recorded on Jan 07, 2015. What about Bitcoin and Stocks? The returns of the apex cryptocurrency pale compared to ETH, as Bitcoin value \$5,295.16% in the same period. \$1,000 would have purchased approximately 2.29 bitcoins on December 23, 2015, which would be worth nearly \$52,956 from press time. On the stock side, investors in Tesla Inc (NASDAQ: TSLA), Amazon.com, Inc (NASDAQ: AMZN) and Apple Inc (NASDAQ: AAPL) reported returns of 1,278.85%, 2,450.02% and 391.72%, respectively. Price Action: ETH was trading 2.17% higher at \$617.13 at the time of the press, while BTC was trading 3.54% higher at \$23,589.53. On Tuesday, Grayscale Ethereum Trust (OTC: ETHE) closed up 7.64% at \$23.40 and Grayscale Bitcoin Trust (OTC: GBTC) closed 1.43% lower at \$30.39. See more from Benzinga \* Click here for Benzinga trading options \* SEC Rule Change On Direct Listings 'Unquestionably' Spells The End-Game For Traditional IPOs , says Bill Gurley \* AstraZeneca to test their COVID-19 vaccine in combination with the Russian Sputnik V(C) Benzinga.com 2020. Benzinga does not provide investment advice. All rights reserved. Spinning Trump's stimulus report did not shake up the actions. China is probing Alibaba. AMD leads 6 chip makers near points of purchase. By John Jannarone, SPAC veteran Eli Baker presented a prospectus for a \$1.5 billion IPO to Zenning Eagle Acquisition Corp., introducing a new innovation that would allow the rightsize vehicle to rotate part of itself if all capital is not needed for a single transaction. President Eagle will raise \$1.5 [-] [-]